liver cancer

Natco Files India’s First Compulsory Licensing Application

September 14, 2011
Patent Commercialisation, Pharma- biotech- Patent Commercialisation

Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent…